Aura Biosciences Secures $161.9 Million in Cash, Ensuring Operational Sustainability Through 2027

Aura Biosciences Inc. has $161.9 million in cash and marketable securities, ensuring operational sustainability until mid-2027. The company focuses on developing precision immunotherapies for solid tumors and maintains a robust balance sheet with a current ratio of 12.39 and a debt-to-equity ratio of 0.1. Despite a challenging stock performance, Aura is positioned in the healthcare sector with a market capitalization of $346.63 million and a strategic focus on precision immunotherapies.